Den systemiske eksponering forventes at være indenfor et veltolereret niveau hos patienter med nedsat leverfunktion, da en 10 gange højere dosis (3 mg/ øje) var veltolereret.
The systemic exposure is expected to be within a well tolerated range in patients with hepatic impairment, as a 10 fold higher dose (3 mg/ eye) was well tolerated.